All statements, other than statements of
historical facts, included in this press release regarding our plans and
objectives of management are forward-looking statements. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, mergers, dispositions, joint
ventures or investments we may make.

blind nairobi

embassy visually

inspiring visually

1 in 10 Children Is At Risk For Undiagnosed Vision Problems

com/broadcast /21952/consumer.

survivor mchugh

is a biopharmaceutical company that
specializes in the development and commercialization of novel therapeutics to
treat diseases of the eye.

astrid lenny

survivor nairobi

retired impaired

Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking statements we
make .

toward retinopathy

I believe Macugen is well positioned to
be a market leader in treating this terribly debilitating disease.

blind retired

Eyetech is commercializing and further developing
Macugen(R) (pegaptanib sodium injection) with Pfizer Inc.

eyesight ellen

newscom.

impaired blinded

Glick continues to be
committed to the success of Eyetech and has entered into an 18-month
consulting contract with the company.

retinopathy programmer

Eyetech Safe Harbor Statement
This press release contains forward-looking statements that involve
substantial risks and uncertainties. We may not actually
achieve the plans, intentions or expectations disclosed in our forward-looking
statements and you should not place undue reliance on our forward-looking
statements. New Public Health Program Provides No-Cost Eye-Assessments for Infants

NEW YORK,

ADDITIONAL RESOURCES: Video, hard copy requests, contact information and
more available at http://www.

VIDEO PROVIDED BY: American Optometric Association

For sites about personal experiences dealing with blindness.

survivor eyesight

shtml

STORY SUMMARY:
Public health experts recommend that parents bring young children to visit
an eye care professional during the first year of his/her life.

retired inspiring

NEW YORK, Eyetech Pharmaceuticals, Inc.

toward prematurity

Macugen is also being studied
for other indications including diabetic macular edema and retinal vein
occlusion . These and other risks are
described in greater detail in the "Risk Factors" section of our 2004 Form 10-
K filed with the SEC.

bombing astrid

(Nasdaq: EYET) announced today that Marty Glick, a co-founder and a director
of the company since its inception in February 2000, has stepped down from the
Board of Directors to pursue personal interests.

recovering programmer

Dr. Guyer and his management team., have partnered to
create InfantSEE(TM), a national no-cost public health program.

prematurity kenya

Mr. Marty has been an
invaluable asset to Eyetech in positioning the company to become a leader in
its field with its strong balance sheet , scientific expertise and partnership
with Pfizer Inc."
(Logo: http://www.com/cgi-bin/prnh /20050407/EYETLOGO )
Marty Glick stated, "It has been an honor and a privilege to work with the
Eyetech team and its Board of Directors over the last five years to get
Macugen approved and launched in the United States as the only drug approved
to treat all forms of neovascular AMD.
Eyetech Pharmaceuticals, Inc. Various important factors could cause actual results or events to differ
materially from the forward-looking statements that we make, including risks
related to: achieving and maintaining acceptance of Macugen by the medical
community, by patients receiving therapy and by third party payors; supplying
sufficient quantities of Macugen to meet anticipated market demand; the impact
of competitive products; our dependence on third parties to manufacture
Macugen; our dependence on our strategic collaboration with Pfizer; obtaining,
maintaining and protecting the intellectual property incorporated into
Macugen; successful recruitment of patients for the clinical development of
Macugen in DME; successful outcomes in the further clinical development of
Macugen; and regulatory approval of Macugen for DME.

astrid embassy

His leadership and experience
in the biotech industry have been invaluable to Eyetech as it has developed
from the clinical stage to marketing, Macugen(R) (pegaptanib sodium
injection), the first FDA-approved drug to treat all forms of neovascular
(wet) age-related macular degeneration (neovascular AMD), the leading cause of
blindness in the elderly and a potential treatment for diabetic macular edema,
the leading cause of vision loss in diabetic retinopathy. On behalf of the entire company, we thank him for his
efforts on the Board and look forward to continue working with him as a
consultant. I look forward to continuing
to work with Dr. Through
InfantSEE(TM ), supported by former president Jimmy Carter, optometrists will
provide a one-time, comprehensive eye exam to infants in their first year of
life, offering early detection of potential vision problems at no cost -
regardless of income.

mchugh toward

To address this need, the American Optometric Association and The Vision
Care Institute of Johnson + Johnson Vision Care, Inc.

nairobi eyesight

lenny retinopathy

David Guyer, Chief Executive Officer
and also a co-founder of Eyetech commented, "We thank Marty for his many
contributions to Eyetech since its' founding. As someone
who is legally blind in my right eye due to the loss of central vision from
myopic macular degeneration, it gives me great pride to know that Macugen may
improve the ability of all patients with neovascular AMD to live more
independently and have a better quality of life."

About Eyetech Pharmaceuticals, Inc. Eyetech's initial focus is on diseases affecting
the back of the eye. According to
the American Optometric Association, 1 in 10 children is at risk from
undiagnosed eye and vision problems, yet only 14 percent of children under age
6 have had a comprehensive eye assessment.

survivor blindness

Eyetech Announces Co-Founder Marty Glick Steps Down From Board To Act As Consultant

ellen astrid

for the treatment of
neovascular age-related macular degeneration . We do not assume any obligation to update
any forward-looking statements.prnewswire. If left undetected , vision
problems can lead to permanent vision impairment and in rare cases, life-
threatening health risks.